331920 — Celemics Balance Sheet
0.000.00%
- KR₩22bn
- KR₩15bn
- KR₩7bn
Annual balance sheet for Celemics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 26,021 | 21,051 | 12,920 | 10,786 | 10,046 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,413 | 1,108 | 1,056 | 743 | 719 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 28,311 | 22,968 | 15,613 | 12,708 | 12,051 |
| Net Property, Plant And Equipment | 1,718 | 3,348 | 3,058 | 2,445 | 1,805 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 30,599 | 26,898 | 22,211 | 18,119 | 29,414 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,143 | 2,025 | 2,645 | 1,649 | 1,971 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1,242 | 3,512 | 3,622 | 2,236 | 2,230 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 29,357 | 23,386 | 18,589 | 15,882 | 27,184 |
| Total Liabilities & Shareholders' Equity | 30,599 | 26,898 | 22,211 | 18,119 | 29,414 |
| Total Common Shares Outstanding |